Medicus pharma ltd receives study may proceed approval from united arab emirates (uae) department of health (doh) to commence phase 2 clinical study (sknjct-004) to non-invasively treat basal cell carcinoma of the skin (bcc)

The clinical study is expected to randomize 36 participants in cleveland clinic abu dhabi (ccad) and three other clinical sites in uae philadelphia, pennsylvania--(newsfile corp. - may 22, 2025) - medicus pharma ltd. (nasdaq: mdcx) ("medicus" or the "company") is pleased to announce that it has received study may proceed approval from the uae doh to commence phase 2 clinical study (sknjct-004) to non-invasively treat bcc of the skin.
BCC Ratings Summary
BCC Quant Ranking